Pulmonx Corporation — FY2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. This is an annual filing; standalone fourth-quarter results are not clearly provided in the filing text summarized here. Pulmonx is a commercial-stage medical-device company focused on severe emphysema, principally selling its Zephyr Endobronchial Valve and related products.
Business context and performance
The Zephyr Valve is used with the Chartis Pulmonary Assessment System and StratX Lung Analysis Platform to select and treat eligible patients. The valve was commercially available in more than 25 countries; the company reported more than 100,000 valves used in over 25,000 patients. Most revenue came from Zephyr Valves and delivery catheters. StratX supports patient assessment but does not independently generate revenue.
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Revenue | $53.7 million | $48.4 million | Up 10.8% |
| Gross profit / margin | $39.9 million / 74.3% | $35.6 million / 73.6% | Margin up 0.7 percentage points |
| Operating expenses | $98.5 million | $82.9 million | Up 18.8% |
| Loss from operations | $58.6 million | $47.3 million | Loss increased |
| Net loss | $58.9 million | $48.7 million | Loss increased 21.1% |
| Net loss per share, diluted | $(1.59) | $(1.35) | Loss per share increased |
| Cash used in operating activities | $45.1 million | $41.4 million | Use increased |
U.S. revenue increased to $32.5 million from $25.0 million, while international revenue declined to $21.2 million from $23.4 million, which management attributed principally to foreign-exchange effects. International sales were 39.5% of revenue, versus 48.4% in 2021. Gross margin improvement reflected better production efficiencies and lower scrap and inventory-reserve expense. Research and development expense rose 17.9% to $15.4 million; selling, general and administrative expense rose 18.9% to $83.1 million, including higher staffing, marketing and travel costs.
Liquidity, debt and cash flow
- At December 31, 2022, cash and cash equivalents were $101.7 million and marketable securities were $45.3 million, totaling $147.1 million; accumulated deficit was $350.3 million.
- Operating cash outflow was $45.1 million. Cash, cash equivalents and restricted cash decreased by $46.7 million during the year. Inventory was $19.8 million, including $5.3 million classified as long-term.
- Year-end debt carrying value was approximately $17.3 million, net of debt discount and issuance costs. The CIBC loan bears a floating rate of 1 percentage point above the Wall Street Journal Prime Rate; its effective rate was 9.1% at year-end. The loan is secured by substantially all company assets.
- An October 2022 amendment extended CIBC loan maturity to October 31, 2027 and provided an option for up to $20.0 million of additional borrowing, subject to conditions. In February 2023, Pulmonx drew that $20.0 million tranche. This subsequent borrowing increases debt and adds covenant requirements.
- Management stated that available cash, cash equivalents and marketable securities were expected to fund planned operations for at least 12 months from issuance of the financial statements. The company nevertheless expects continued losses and negative operating cash flows and may need additional financing.
Outlook, risks and unusual items
- Outlook: No specific revenue or earnings guidance is provided in the filing text. Management plans to expand commercial operations and continue product development, clinical work and investment in sales and marketing, and expects losses for the next several years.
- Demand and reimbursement: Procedure volumes recovered in the U.S. and some international markets, but recovery remained slower in other regions. COVID-19, hospital capacity and staffing constraints, physician adoption, and case-by-case Medicare and commercial-payor coverage remain relevant risks.
- Clinical and product safety: Pneumothorax occurred in 18%–34% of patients treated in cited clinical trials. The filing also describes four treatment-period deaths in the Zephyr arm of the LIBERATE study, which investigators deemed definitely or probably treatment-related. Longer-term follow-up results were expected in Q2 2023.
- Government investigation: In December 2022, the company received a Department of Justice civil investigative demand concerning relationships with certain healthcare providers, medical practices and hospitals in connection with Zephyr sales and marketing. Pulmonx said it was cooperating, but could not estimate the outcome or a reasonably possible loss; the outcome could materially affect the business and financial results.
- Other exposures: The company depends on single-source suppliers and a Redwood City manufacturing site, and faces regulatory, product-liability, cybersecurity, foreign-exchange and competitive risks. It does not currently hedge foreign-currency exposure and reported no cyber insurance.
- Development: AeriSeal is in development for patients who may not qualify for Zephyr treatment because of collateral ventilation. Pulmonx intended to submit an IDE to the FDA to begin a clinical trial; commercial success and regulatory approval are uncertain.
- Controls and audit: Management reported effective disclosure controls and internal control over financial reporting at year-end and said a previously reported material weakness involving IT access and segregation of duties had been remediated. The auditor issued an unqualified opinion on the financial statements; it did not express an opinion on internal-control effectiveness.
Most important facts for investors to verify
- Review the DOJ investigation’s scope, subsequent developments, and any eventual estimate or disclosure of potential financial or operational impact.
- Assess the effect of the February 2023 $20.0 million CIBC draw on cash runway, interest expense, repayment obligations and covenant compliance.
- Compare future U.S. procedure growth with international revenue trends and reported foreign-exchange effects; confirm whether recovery and reimbursement access are broadening.
- Monitor the LIBERATE extension-study results and post-market safety data, especially pneumothorax rates and treatment-related outcomes.
- Track quarterly operating cash burn, inventory levels and long-term inventory assumptions; the auditor identified inventory classification as a critical audit matter.
- Check progress on the AeriSeal IDE and other development plans, as well as regulatory-transition requirements in Europe.